NPL insulin — Competitive Intelligence Brief

NPL insulin (NPL insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog. Area: Diabetes.

marketed Insulin analog Insulin receptor Diabetes Small molecule

Target snapshot

NPL insulin (NPL insulin) — University of Campania Luigi Vanvitelli. NPL insulin is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage in peripheral tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NPL insulin TARGET	NPL insulin	University of Campania Luigi Vanvitelli	marketed	Insulin analog	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog class)

1. Generex Biotechnology Corp. · 1 drug in this class
2. Mylan Inc. · 1 drug in this class
3. National Institute of Neurosciences and Hospital, Dhaka · 1 drug in this class
4. University of Campania Luigi Vanvitelli · 1 drug in this class